Evidence map›Paper›PMID 36155169›Full record

ArticleClinical genitourinary cancer2022

Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma.

Rafee Talukder, Dimitrios Makrakis, Genevieve Ihsiu Lin, Leonidas N Diamantopoulos, Scott Dawsey, Shilpa Gupta, Lucia Carril-Ajuria, Daniel Castellano, Ivan de Kouchkovsky, Tanya Jindal and 44 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical genitourinary cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

54 authors at 20 institutions in 7 countries.

Rafee TalukderDivision of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA.
Dimitrios MakrakisDivision of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA.
Genevieve Ihsiu LinDepartment of Epidemiology, University of Washington, Seattle, WA.
Leonidas N DiamantopoulosDepartment of Medicine, University of Pittsburgh, Pittsburgh, PA.
Scott DawseyDepartment of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH.
Shilpa GuptaDepartment of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH.
Lucia Carril-AjuriaDepartment of Medical Oncology, Hospital Universitario, Madrid, Spain.
Daniel CastellanoDepartment of Medical Oncology, Hospital Universitario, Madrid, Spain.
Ivan de KouchkovskyDivision of Oncology, Department of Medicine, University of California, San Francisco, CA.
Tanya JindalDivision of Oncology, Department of Medicine, University of California, San Francisco, CA.
Vadim S KoshkinDivision of Oncology, Department of Medicine, University of California, San Francisco, CA.
Joseph J ParkDivision of Oncology, Department of Medicine, University of Michigan, Ann Arbor, MI.
Ajjai AlvaDivision of Oncology, Department of Medicine, University of Michigan, Ann Arbor, MI.
Mehmet A BilenWinship Cancer Institute of Emory University, Atlanta, GA.
Tyler F StewartDivision of Hematology/Oncology, Department of Medicine, University of California San Diego, La Jolla, CA.
Rana R McKayDivision of Hematology/Oncology, Department of Medicine, University of California San Diego, La Jolla, CA.
Nishita TripathiDivision of Oncology, Department of Medicine, University of Utah, Salt Lake City, UT.
Neeraj AgarwalDivision of Oncology, Department of Medicine, University of Utah, Salt Lake City, UT.
Naomi Vather-WuDepartment of Medicine, University of Iowa, Iowa City, IA.
Yousef ZakhariaDivision of Oncology, Department of Medicine, University of Iowa, Iowa City, IA.
Rafael Morales-BarreraVall d'Hebron Institute of Oncology, Vall d' Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.
Michael E DevittDivision of Hematology/Oncology, Department of Medicine, University of Virginia School of Medicine, Charlottesville, VA.
Alessio CortelliniDepartment of Surgery and Cancer, Imperial College London, London.
Claudia Angela Maria FulgenziDepartment of Surgery and Cancer, Imperial College London, London.
David J PinatoDepartment of Surgery and Cancer, Imperial College London, London.
Ariel NelsonDivision of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.
Christopher J HoimesDivision of Medical Oncology, Seidman Cancer Center at Case Comprehensive Cancer Center, Cleveland, OH; Division of Medical Oncology, Duke University, Durham, NC.
Kavita GuptaDepartments of Medical Oncology and Urology, Montefiore Medical Center, Bronx, NY.
Benjamin A GartrellDepartments of Medical Oncology and Urology, Montefiore Medical Center, Bronx, NY.
Alex SankinDepartments of Medical Oncology and Urology, Montefiore Medical Center, Bronx, NY.
Abhishek TripathiStephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK.
Roubini ZakopoulouDepartment of Clinical Therapeutics, Alexandra General Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
Aristotelis Bamias2nd Propaedeutic Department of Internal Medicine, ATTIKON University Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
Jure MurgicDepartment of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb.
Ana FröbeDepartment of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, Zagreb; School of Dental Medicine, Zagreb, Croatia.
Alejo Rodriguez-VidaMedical Oncology Department, Hospital del Mar Research Institute, Barcelona, Spain.
Alexandra DrakakiDivision of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA.
Sandy LiuDivision of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA.
Eric LuDivision of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA.
Vivek KumarDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Giuseppe Di LorenzoOncology University of Molise and ASL, Salerno, Italy.
Monika JoshiDivision of Hematology/Oncology, Department of Medicine, Penn State Cancer Institute, Hershey, PA.
Pedro Isaacsson-VelhoDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Division of Oncology, Hospital Moinhos de Vento, Porto Alegre, Brazil.
Lucia Alonso BuznegoHospital Universitario Marques de Valdecilla. IDIVAL. Santander, Spain.
Ignacio DuranHospital Universitario Marques de Valdecilla. IDIVAL. Santander, Spain.
Marcus MosesDeming Department of Medicine, Section of Hematology/Oncology, Tulane University, New Orleans, LA.
Pedro BarataDeming Department of Medicine, Section of Hematology/Oncology, Tulane University, New Orleans, LA.
Guru SonpavdeGenitourinary Oncology Program, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Jonathan L WrightFred Hutchinson Cancer Center, Seattle, WA; Department of Urology, University of Washington, Seattle, WA.
Evan Y YuDivision of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA; Fred Hutchinson Cancer Center, Seattle, WA.
Robert Bruce MontgomeryDivision of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA; Fred Hutchinson Cancer Center, Seattle, WA.
Andrew C HsiehDivision of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA; Fred Hutchinson Cancer Center, Seattle, WA.
Petros GrivasDivision of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA; Fred Hutchinson Cancer Center, Seattle, WA. Electronic address: pgrivas@uw.edu.
Ali Raza KhakiDivision of Oncology, Department of Medicine, Stanford University, Palo Alto, CA. Electronic address: alikhaki@stanford.edu.
University of Washington Medical Center · USImperial College London · GBMontefiore Medical Center · USUniversity of California, Los Angeles · USUniversity of California, San Francisco · USCleveland Clinic · USHospital Universitario HM Madrid · ESInstituto de Investigación Marqués de Valdecilla · ESNational and Kapodistrian University of Athens · GRTulane University · USUniversity of California San Diego · USUniversity of Iowa · USUniversity of Michigan · USUniversity of Utah · USBrigham and Women's Hospital · USEmory University · USFred Hutch Cancer Center · USHarvard University · USHospital Del Mar · ESHospital Moinhos de Vento · BR

Funding

VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jesse Nodora · 1985 to 2026
$124.9M
Transform Dissemination and Implementation Science in CTSA ProgramsUL1TR002319 · NCATS · UNIVERSITY OF WASHINGTON · PI John K. Amory · 2017 to 2026
$100.0M
NCATS NIH HHS UL1 TR002319NCI NIH HHS P30 CA023100
6 · The paper itself

Abstract

backgroundEarly progression on first-line (1L) platinum-based therapy or between therapy lines may be a surrogate of more aggressive disease and poor outcomes in advanced urothelial carcinoma (aUC), but its prognostic role regarding immune checkpoint inhibitor (ICI) response and survival is unclear. We hypothesized that shorter time until start of second-line (2L) ICI would be associated with worse outcomes in aUC. PATIENTS AND

methodsWe performed a retrospective multi-institution cohort study in patients with aUC treated with 1L platinum-based chemotherapy, who received 2L ICI. Patients receiving switch maintenance ICI were excluded. We defined time to 2L ICI therapy as the time between the start of 1L platinum-based chemotherapy to the start of 2L ICI and categorized patients a priori into 1 of 3 groups: less than 3 months versus 3-6 months versus more than 6 months. We calculated overall response rate (ORR) with 2L ICI, progression-free survival (PFS) and overall survival (OS) from the start of 2L ICI. ORR was compared among the 3 groups using multivariable logistic regression, and PFS, OS using cox regression. Multivariable models were adjusted for known prognostic factors.

resultsWe included 215, 215, and 219 patients in the ORR, PFS, and OS analyses, respectively, after exclusions. ORR difference did not reach statistical significance between patients with less than 3 months versus 3-6 months versus more than 6 months to 2L ICI. However, PFS (HR 1.64; 95% CI 1.02-2.63) and OS (HR 1.77; 95% CI 1.10-2.84) was shorter among those with time to 2L ICI less than 3 months compared to those who initiated 2L ICI more than 6 months.

conclusionAmong patients with aUC treated with 2L ICI, time to 2L ICI less than 3 months was associated with lower, but not significantly different ORR, but shorter PFS and OS compared to 2L ICI more than 6 months. This highlights potential cross resistance mechanisms between ICI and platinum-based chemotherapy.

Indexed as

Carcinoma, Transitional CellUrinary Bladder NeoplasmsCohort StudiesHumansImmune Checkpoint InhibitorsRetrospective StudiesTreatment OutcomeImmune Checkpoint InhibitorsBladder cancerCheckpoint InhibitorImmunotherapyOutcomesPlatinum resistance

Identifiers

PMID36155169
PMCPMC10233855
OpenAlexW4292382926

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.